{"id":395709,"date":"2020-12-08T12:24:02","date_gmt":"2020-12-08T17:24:02","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=395709"},"modified":"2020-12-08T12:24:02","modified_gmt":"2020-12-08T17:24:02","slug":"ec-mergers-acquisitions-advised-artesyn-on-its-sale-to-repligen","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ec-mergers-acquisitions-advised-artesyn-on-its-sale-to-repligen\/","title":{"rendered":"EC Mergers & Acquisitions advised ARTeSYN on its Sale to Repligen"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n NEW YORK<\/span>, Dec. 8, 2020<\/span> \/PRNewswire\/ —\u00a0EC Mergers & Acquisitions<\/a> (“EC M&A”) is pleased to confirm the sale of ARTeSYN BioSolutions (“ARTeSYN”)<\/p>\n

\n

\n
\n \"EC
\n <\/a>\n <\/p>\n<\/p><\/div>\n

\n ARTeSYN<\/a> is a manufacturer of innovative single-use solutions for the downstream bioprocessing industry. The Company is growing rapidly, led by the success of its single-use chromatography and filtration systems which are considered the gold standards in downstream bioprocessing due to their performance, automation and low hold-up volumes. ARTeSYN’s suite of single-use solutions have been created with the goal of enabling abundance in medicine by allowing 10x greater efficiency in biologics manufacturing. Over the past decade, ARTeSYN has established downstream processing leadership with a suite of state of the art single-use systems for chromatography, filtration, continuous manufacturing and media\/buffer prep workflows. In addition, the Company has integrated unique flow path assemblies to deliver highly differentiated, low hold-up volume systems that minimize product loss during processing. ARTeSYN’s product portfolio also includes single-use valves with fully disposable valve liners, XO\u00ae skeletal supports and a hybrid small parts offering for de-bottlenecking traditional facilities. The Company is headquartered in Waterford, Ireland<\/span> with additional locations in the United States<\/span> and Estonia<\/span>.<\/p>\n

\n Repligen Corporation<\/a> (NASDAQ: RGEN) is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that increase efficiencies in the process of manufacturing biological drugs. Repligen’s mission is to inspire advances in bioprocessing for biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide.<\/p>\n

\n Michael Gagne<\/span> founder of ARTeSYN said, “We were thrilled with the opportunity to partner with EC M&A on this transaction. EC M&A patiently and professionally supported us in our evaluation of numerous different offers and opportunities, including potential capital raises, partnership with various growth equity funds, and tremendous offers from various strategic acquirers. In the end, with EC M&A’s support and counsel, we moved forward with Repligen Corporation. We believe Repligen is the perfect partner to continue the development of ARTeSYN BioSolutions and pursue my goal of enabling abundance in medicine.”\u00a0\u00a0<\/p>\n

The transaction totals $200M<\/span>, $130M<\/span> of which will be paid in cash and $70M<\/span> in Repligen common stock. ARTeSYN is projected to generate approximately $30M<\/span> in pro forma revenue in 2020, representing 6x-7x 2020e revenue. The business is expected to contribute approximately $33M<\/span>–36M<\/span> of revenue in 2021E.<\/p>\n

\n About EC Mergers & Acquisitions
<\/b>EC M&A is a premier middle-market advisory firm, having advised on over 275 completed life sciences and industrial technologies transactions. Since 1992, we have developed strong relationships with many of the most innovative companies in biopharma technologies, life sciences, medical devices, industrial technologies, and digital solutions. Our focus is generating highly compelling valuations by virtue of our deep domain expertise and genuine global buyer access for middle market life sciences and industrial technology transactions.\u00a0 EC M&A offers global, seamless client coverage and senior-level attention across our offices in New York<\/span>, Chicago<\/span>, London<\/span>, Paris<\/span>, Frankfurt<\/span>, Prague<\/span>, Zurich<\/span>, Milan<\/span>, Beijing<\/span> and Hong Kong<\/span>. www.ec-ma.com<\/a><\/p>\n

\n Contact
<\/b>
\n Richard Hale<\/span>
\n
+44 (0) 207 665 6869
richard.hale@ec-ma.com<\/a><\/p>\n

<\/div>\n

\n \"Cision\" View original content to download multimedia:http:\/\/www.prnewswire.com\/news-releases\/ec-mergers–acquisitions-advised-artesyn-on-its-sale-to-repligen-301188629.html<\/a><\/p>\n

SOURCE EC M&A<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire NEW YORK, Dec. 8, 2020 \/PRNewswire\/ —\u00a0EC Mergers & Acquisitions (“EC M&A”) is pleased to confirm the sale of ARTeSYN BioSolutions (“ARTeSYN”) ARTeSYN is a manufacturer of innovative single-use solutions for the downstream bioprocessing industry. The Company is growing rapidly, led by the success of its single-use chromatography and filtration systems which are considered the gold standards in downstream bioprocessing due to their performance, automation and low hold-up volumes. ARTeSYN’s suite of single-use solutions have been created with the goal of enabling abundance in medicine by allowing 10x greater efficiency in biologics manufacturing. Over the past decade, ARTeSYN has established downstream processing leadership with a suite of state of the art single-use systems for chromatography, filtration, continuous manufacturing … <\/p>\n

Continue reading “EC Mergers & Acquisitions advised ARTeSYN on its Sale to Repligen”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-395709","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nEC Mergers & Acquisitions advised ARTeSYN on its Sale to Repligen - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ec-mergers-acquisitions-advised-artesyn-on-its-sale-to-repligen\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"EC Mergers & Acquisitions advised ARTeSYN on its Sale to Repligen - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire NEW YORK, Dec. 8, 2020 \/PRNewswire\/ —\u00a0EC Mergers & Acquisitions (“EC M&A”) is pleased to confirm the sale of ARTeSYN BioSolutions (“ARTeSYN”) ARTeSYN is a manufacturer of innovative single-use solutions for the downstream bioprocessing industry. The Company is growing rapidly, led by the success of its single-use chromatography and filtration systems which are considered the gold standards in downstream bioprocessing due to their performance, automation and low hold-up volumes. ARTeSYN’s suite of single-use solutions have been created with the goal of enabling abundance in medicine by allowing 10x greater efficiency in biologics manufacturing. Over the past decade, ARTeSYN has established downstream processing leadership with a suite of state of the art single-use systems for chromatography, filtration, continuous manufacturing … Continue reading "EC Mergers & Acquisitions advised ARTeSYN on its Sale to Repligen"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/ec-mergers-acquisitions-advised-artesyn-on-its-sale-to-repligen\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-08T17:24:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/1326954\/EC_M_A_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ec-mergers-acquisitions-advised-artesyn-on-its-sale-to-repligen\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ec-mergers-acquisitions-advised-artesyn-on-its-sale-to-repligen\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"EC Mergers & Acquisitions advised ARTeSYN on its Sale to Repligen\",\"datePublished\":\"2020-12-08T17:24:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ec-mergers-acquisitions-advised-artesyn-on-its-sale-to-repligen\\\/\"},\"wordCount\":533,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ec-mergers-acquisitions-advised-artesyn-on-its-sale-to-repligen\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1326954\\\/EC_M_A_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ec-mergers-acquisitions-advised-artesyn-on-its-sale-to-repligen\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ec-mergers-acquisitions-advised-artesyn-on-its-sale-to-repligen\\\/\",\"name\":\"EC Mergers & Acquisitions advised ARTeSYN on its Sale to Repligen - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ec-mergers-acquisitions-advised-artesyn-on-its-sale-to-repligen\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ec-mergers-acquisitions-advised-artesyn-on-its-sale-to-repligen\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1326954\\\/EC_M_A_Logo.jpg\",\"datePublished\":\"2020-12-08T17:24:02+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ec-mergers-acquisitions-advised-artesyn-on-its-sale-to-repligen\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ec-mergers-acquisitions-advised-artesyn-on-its-sale-to-repligen\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ec-mergers-acquisitions-advised-artesyn-on-its-sale-to-repligen\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1326954\\\/EC_M_A_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1326954\\\/EC_M_A_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ec-mergers-acquisitions-advised-artesyn-on-its-sale-to-repligen\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"EC Mergers & Acquisitions advised ARTeSYN on its Sale to Repligen\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"EC Mergers & Acquisitions advised ARTeSYN on its Sale to Repligen - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/ec-mergers-acquisitions-advised-artesyn-on-its-sale-to-repligen\/","og_locale":"en_US","og_type":"article","og_title":"EC Mergers & Acquisitions advised ARTeSYN on its Sale to Repligen - Market Newsdesk","og_description":"PR Newswire NEW YORK, Dec. 8, 2020 \/PRNewswire\/ —\u00a0EC Mergers & Acquisitions (“EC M&A”) is pleased to confirm the sale of ARTeSYN BioSolutions (“ARTeSYN”) ARTeSYN is a manufacturer of innovative single-use solutions for the downstream bioprocessing industry. The Company is growing rapidly, led by the success of its single-use chromatography and filtration systems which are considered the gold standards in downstream bioprocessing due to their performance, automation and low hold-up volumes. ARTeSYN’s suite of single-use solutions have been created with the goal of enabling abundance in medicine by allowing 10x greater efficiency in biologics manufacturing. Over the past decade, ARTeSYN has established downstream processing leadership with a suite of state of the art single-use systems for chromatography, filtration, continuous manufacturing … Continue reading \"EC Mergers & Acquisitions advised ARTeSYN on its Sale to Repligen\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/ec-mergers-acquisitions-advised-artesyn-on-its-sale-to-repligen\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-08T17:24:02+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/1326954\/EC_M_A_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ec-mergers-acquisitions-advised-artesyn-on-its-sale-to-repligen\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ec-mergers-acquisitions-advised-artesyn-on-its-sale-to-repligen\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"EC Mergers & Acquisitions advised ARTeSYN on its Sale to Repligen","datePublished":"2020-12-08T17:24:02+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ec-mergers-acquisitions-advised-artesyn-on-its-sale-to-repligen\/"},"wordCount":533,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ec-mergers-acquisitions-advised-artesyn-on-its-sale-to-repligen\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1326954\/EC_M_A_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ec-mergers-acquisitions-advised-artesyn-on-its-sale-to-repligen\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/ec-mergers-acquisitions-advised-artesyn-on-its-sale-to-repligen\/","name":"EC Mergers & Acquisitions advised ARTeSYN on its Sale to Repligen - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ec-mergers-acquisitions-advised-artesyn-on-its-sale-to-repligen\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ec-mergers-acquisitions-advised-artesyn-on-its-sale-to-repligen\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1326954\/EC_M_A_Logo.jpg","datePublished":"2020-12-08T17:24:02+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ec-mergers-acquisitions-advised-artesyn-on-its-sale-to-repligen\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/ec-mergers-acquisitions-advised-artesyn-on-its-sale-to-repligen\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ec-mergers-acquisitions-advised-artesyn-on-its-sale-to-repligen\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/1326954\/EC_M_A_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/1326954\/EC_M_A_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ec-mergers-acquisitions-advised-artesyn-on-its-sale-to-repligen\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"EC Mergers & Acquisitions advised ARTeSYN on its Sale to Repligen"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/395709","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=395709"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/395709\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=395709"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=395709"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=395709"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}